LA JOLLA, Calif. ( TheStreet) -- Orexigen Therapeutics (OREX) won't have a weight-loss pill approved and ready for sale until well into 2014 but its stock is generating far greater returns this year than rivals Arena Pharmaceuticals (ARNA) and Vivus (VVUS) with drugs already on the market.
Shares of Orexigen are up 12% this year, which makes it the only obesity drug stock making money for investors. Vivus shares are down 8% while Arena has lost 22% of its value.
Vivus botched the commercial launch of its Qsymia weight-loss pill and is now fighting off a dissident shareholder, First Manhattan, which wants to replace the company's board of directors and management team. For Arena, the first few weeks of prescription data reported for the early Belviq launch have done nothing to shake investors' perception that its drug is ineffectual.Orexigen is still conducting a large cardiovascular safety study of its obesity pill Contrave, with an interim analysis and results expected in the third quarter. If Contrave gets a passing grade from the study, the drug will be resubmitted to the FDA by the end of the year or in early 2014, the company has said. Anticipation for the Contrave heart-safety study results is one explanation for the outperformance of Orexigen shares this year, but so is the company's relatively low valuation compared to Arena and Vivus. At the start of the year, Orexigen's market value of $488 million was dwarfed by Arena ($2.1 billion market cap) and Vivus ($1.5 billion market cap.) Through the first half of the year, the valuation gap between the three companies has narrrowed somewhat. OREX Market Cap data by YCharts
Contrave is a pill combining two already-approved medicines -- bupropion and naltrexone. Efficacy-wise, Contrave demonstrated greater weight loss than Arena's Belviq but less than Vivus' Qsymia. Being the third obesity pill to launch commercially may be seen as a disadvantage, but of all three companies, Orexigen has the best, most experienced marketing partner in Takeda. The diabetes drug Actos is a blockbuster product for Takeda, which will leverage that metabolic drug marketing expertise when Contrave hits the market. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV